FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896690910> ?p ?o ?g. }

• W2896690910 endingPage "138" @default.
• W2896690910 startingPage "133" @default.
• W2896690910 abstract "Background Over the last decade, therapy of relapsing remitting multiple sclerosis (RRMS) has evolved with the approval of several new treatment concepts. Thus, treatment goals have become more ambitious aiming at “no evidence of disease activity” (NEDA). As NEDA-3, this concept comprises freedom of clinical disease progression and relapses as well as inflammatory MRI activity. So far, data on NEDA status mainly stem from post-hoc analyses of drug approval studies. Yet, less is known about the significance of NEDA in “real-world” clinical settings. Hence, our study aims at investigation of NEDA in a heterogeneous cohort of relapsing MS patients. Methods This is a retrospective single-center study at the Department of Neurology of the University Hospital Erlangen, Germany, including data of 306 patients with relapsing forms of MS (RMS) or clinical isolated syndrome (CIS) from 2009 to 2016. Inclusion required sufficient clinical information and in house cranial MRI follow-up data sets at baseline and at follow-up after one year with a potential extension to two and three year follow-up, if possible. NEDA-3 status, its correlation to clinical features, associated medication and NEDA failure (EDA) were analyzed. Results In a cohort of RMS patients at the early stages of the disease (median EDSS 1.5, mean disease duration 30 months) at baseline, 45% retained NEDA-3 status after one year. This percentage decreased in year two (29%) and three (21%) of follow-up. MRI criteria were responsible for loss of NEDA status in 64% of cases and CIS patients were more likely to sustain NEDA status. Therapy with monoclonal antibodies appeared superior in sustaining NEDA status as compared to injectables or oral treatment options. Discussion In our real-world analysis, we confirm the potential of NEDA for the evaluation and surveillance of MS disease activity, progression and therapy efficacy. Despite highly efficient immunomodulatory treatment, NEDA-3 was only preserved in a minority of patients. Monoclonal antibodies may yield best NEDA rates. Further studies are warranted to evaluate the value of the NEDA concept in real-world settings beyond standardized clinical studies." @default.
• W2896690910 created "2018-10-26" @default.
• W2896690910 creator A5005920666 @default.
• W2896690910 creator A5006554131 @default.
• W2896690910 creator A5015953298 @default.
• W2896690910 creator A5033348686 @default.
• W2896690910 creator A5049232836 @default.
• W2896690910 creator A5063613735 @default.
• W2896690910 creator A5064617314 @default.
• W2896690910 creator A5073284312 @default.
• W2896690910 creator A5076511422 @default.
• W2896690910 creator A5082340483 @default.
• W2896690910 date "2019-01-01" @default.
• W2896690910 modified "2023-10-14" @default.
• W2896690910 title "No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany" @default.
• W2896690910 cites W149655820 @default.
• W2896690910 cites W1512495229 @default.
• W2896690910 cites W1966849321 @default.
• W2896690910 cites W1972752407 @default.
• W2896690910 cites W1999493557 @default.
• W2896690910 cites W2015285729 @default.
• W2896690910 cites W2030992801 @default.
• W2896690910 cites W2037557484 @default.
• W2896690910 cites W2041351053 @default.
• W2896690910 cites W2085730152 @default.
• W2896690910 cites W2105053272 @default.
• W2896690910 cites W2112165124 @default.
• W2896690910 cites W2122545833 @default.
• W2896690910 cites W2123021165 @default.
• W2896690910 cites W2143771994 @default.
• W2896690910 cites W2145097697 @default.
• W2896690910 cites W2151423278 @default.
• W2896690910 cites W2171100984 @default.
• W2896690910 cites W2171105288 @default.
• W2896690910 cites W2173315418 @default.
• W2896690910 cites W2257766930 @default.
• W2896690910 cites W2280334572 @default.
• W2896690910 cites W2283020736 @default.
• W2896690910 cites W2299845585 @default.
• W2896690910 cites W2404436371 @default.
• W2896690910 cites W2405536231 @default.
• W2896690910 cites W2466487239 @default.
• W2896690910 cites W2489432788 @default.
• W2896690910 cites W2530203323 @default.
• W2896690910 cites W2555514711 @default.
• W2896690910 cites W2603979662 @default.
• W2896690910 cites W2605302503 @default.
• W2896690910 cites W2621877210 @default.
• W2896690910 cites W2744884072 @default.
• W2896690910 cites W2776813496 @default.
• W2896690910 cites W2777074421 @default.
• W2896690910 cites W2783237032 @default.
• W2896690910 cites W2801888149 @default.
• W2896690910 doi "https://doi.org/10.1016/j.msard.2018.10.020" @default.
• W2896690910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30384198" @default.
• W2896690910 hasPublicationYear "2019" @default.
• W2896690910 type Work @default.
• W2896690910 sameAs 2896690910 @default.
• W2896690910 citedByCount "10" @default.
• W2896690910 countsByYear W28966909102019 @default.
• W2896690910 countsByYear W28966909102020 @default.
• W2896690910 countsByYear W28966909102021 @default.
• W2896690910 countsByYear W28966909102022 @default.
• W2896690910 countsByYear W28966909102023 @default.
• W2896690910 crossrefType "journal-article" @default.
• W2896690910 hasAuthorship W2896690910A5005920666 @default.
• W2896690910 hasAuthorship W2896690910A5006554131 @default.
• W2896690910 hasAuthorship W2896690910A5015953298 @default.
• W2896690910 hasAuthorship W2896690910A5033348686 @default.
• W2896690910 hasAuthorship W2896690910A5049232836 @default.
• W2896690910 hasAuthorship W2896690910A5063613735 @default.
• W2896690910 hasAuthorship W2896690910A5064617314 @default.
• W2896690910 hasAuthorship W2896690910A5073284312 @default.
• W2896690910 hasAuthorship W2896690910A5076511422 @default.
• W2896690910 hasAuthorship W2896690910A5082340483 @default.
• W2896690910 hasConcept C118552586 @default.
• W2896690910 hasConcept C126322002 @default.
• W2896690910 hasConcept C16568411 @default.
• W2896690910 hasConcept C167135981 @default.
• W2896690910 hasConcept C187212893 @default.
• W2896690910 hasConcept C201903717 @default.
• W2896690910 hasConcept C2779134260 @default.
• W2896690910 hasConcept C2780640218 @default.
• W2896690910 hasConcept C71924100 @default.
• W2896690910 hasConcept C72563966 @default.
• W2896690910 hasConceptScore W2896690910C118552586 @default.
• W2896690910 hasConceptScore W2896690910C126322002 @default.
• W2896690910 hasConceptScore W2896690910C16568411 @default.
• W2896690910 hasConceptScore W2896690910C167135981 @default.
• W2896690910 hasConceptScore W2896690910C187212893 @default.
• W2896690910 hasConceptScore W2896690910C201903717 @default.
• W2896690910 hasConceptScore W2896690910C2779134260 @default.
• W2896690910 hasConceptScore W2896690910C2780640218 @default.
• W2896690910 hasConceptScore W2896690910C71924100 @default.
• W2896690910 hasConceptScore W2896690910C72563966 @default.
• W2896690910 hasLocation W28966909101 @default.
• W2896690910 hasLocation W28966909102 @default.
• W2896690910 hasOpenAccess W2896690910 @default.

• next